{
  "first_published_at": "2007-08-01", 
  "original_url": "http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON079101", 
  "title": "Linezolid: restricted indication", 
  "tags": "{\"parsed_therapeutic\": [\"infectious-disease\"], \"Audience:\": [\"Secondary care\"], \"Therapeutic area:\": [\"Infectious disease\"]}", 
  "_document_number": 330, 
  "label": null, 
  "icon": "http://www.mhra.gov.uk/home/images/MHRALook/img/dsu/change_icon.png", 
  "therapeutic_area": [
    "infectious-disease"
  ], 
  "raw_html": "<div id=\"dsuArticleContent\">\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<h1><a name=\"maincontent\" id=\"maincontent\"></a>Linezolid: restricted indication</h1>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<span class=\"ref\">Article date: August 2007</span> \r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t<!---->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<div id=\"dsuSynopsis\" class=\"yellow\">\r\n\t\t\t\t\t\t\t\t\t<div class=\"dsuArticlePadding\">\r\n\t\t\t\t\t\t\t\t\t<span id=\"dsuSynopsisTitle\"><b>Summary</b></span>\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<br>Linezolid is not active against infections caused by Gram-negative pathogens, and treatment should be started only after specialist microbiological advice<br>\t\r\n\t\t\t\t\t\t\t\t\t</div>         \t\t\r\n\t\t\t\t\t\t\t\t\t<div id=\"dsuSynopsisCut\">\r\n\t\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t<!--<p>Linezolid (Zyvox&#9660;) is an oxazolidinone antimicrobial, which selectively inhibits bacterial ribosomal translation; it also acts as a reversible monoamine oxidase inhibitor. Linezolid is indicated for treatment of nosocomial pneumonia, community acquired pneumonia, and complicated skin and soft tissue infections. Clinical efficacy has been shown for the Gram-positive aerobes <em>Enterococcus faecium</em>, <em>Staphylococcus aureus</em>, <em>Streptococcus agalactiae</em>, <em>Streptococcus pneumoniae</em>, and <em>Streptococcus pyogenes</em>.</p><p>A study of intravascular catheter-related infections has shown increased mortality in patients who were treated with linezolid (78 of 363 [21&middot;5%]) compared with those who were treated with vancomycin, dicloxacillin, or oxacillin (58 of 363 [16&middot;0%]). The greatest imbalance occurred during treatment and within 7 days after discontinuation of study drug (43 of 363 [12%] deaths in the linezolid arm <em>vs</em> 22 of 363 [6%] in comparator arm). Mortality did not differ between groups of patients with pure Gram-positive infection (odds ratio 0&middot;96 [95% CI 0&middot;58&ndash;1&middot;59]), but was significantly higher in the linezolid arm for patients with any other pathogen or no pathogen at baseline (2&middot;48 [1&middot;38&ndash;4&middot;46], p=0&middot;0162). More patients in the linezolid arm than in the comparator arm acquired Gram-negative infections during the study and died from Gram-negative and polymicrobial infections.</p><p>Prescribing advice for linezolid was updated in March, 2007: linezolid is now indicated for treatment of complicated skin and soft tissue infections <strong>only</strong> when microbiological testing has established that infection is caused by susceptible Gram-positive bacteria. Patients with complicated skin and soft tissue infections who have known or possible co-infection with Gram-negative organisms should receive linezolid only if no alternative treatment options are available. In these circumstances, treatment against Gram-negative organisms must be initiated concomitantly.</p><p>Specific Gram-negative treatment <em><strong>must</strong></em> be initiated concomitantly if a Gram-negative pathogen is documented or suspected in patients with nosocomial or community acquired pneumonia.</p><p>Linezolid should be initiated only in a hospital environment and after consultation with a relevant specialist such as a microbiologist.</p><p>For further information see <span><u><a href=\"http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines/CON2030643\" target=\"_blank\"><font color=\"#800080\">Letter sent to healthcare professionals in March 2007</font></a></u></span></p><p>&nbsp;</p><p><em>Article citation: Drug Safety Update August 2007; Vol 1, issue 1: 6-7.</em></p>-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t\t<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t<p>Linezolid (Zyvox&#9660;) is an oxazolidinone antimicrobial, which selectively inhibits bacterial ribosomal translation; it also acts as a reversible monoamine oxidase inhibitor. Linezolid is indicated for treatment of nosocomial pneumonia, community acquired pneumonia, and complicated skin and soft tissue infections. Clinical efficacy has been shown for the Gram-positive aerobes <em>Enterococcus faecium</em>, <em>Staphylococcus aureus</em>, <em>Streptococcus agalactiae</em>, <em>Streptococcus pneumoniae</em>, and <em>Streptococcus pyogenes</em>.</p><p>A study of intravascular catheter-related infections has shown increased mortality in patients who were treated with linezolid (78 of 363 [21&#183;5%]) compared with those who were treated with vancomycin, dicloxacillin, or oxacillin (58 of 363 [16&#183;0%]). The greatest imbalance occurred during treatment and within 7 days after discontinuation of study drug (43 of 363 [12%] deaths in the linezolid arm <em>vs</em> 22 of 363 [6%] in comparator arm). Mortality did not differ between groups of patients with pure Gram-positive infection (odds ratio 0&#183;96 [95% CI 0&#183;58&#8211;1&#183;59]), but was significantly higher in the linezolid arm for patients with any other pathogen or no pathogen at baseline (2&#183;48 [1&#183;38&#8211;4&#183;46], p=0&#183;0162). More patients in the linezolid arm than in the comparator arm acquired Gram-negative infections during the study and died from Gram-negative and polymicrobial infections.</p><p>Prescribing advice for linezolid was updated in March, 2007: linezolid is now indicated for treatment of complicated skin and soft tissue infections <strong>only</strong> when microbiological testing has established that infection is caused by susceptible Gram-positive bacteria. Patients with complicated skin and soft tissue infections who have known or possible co-infection with Gram-negative organisms should receive linezolid only if no alternative treatment options are available. In these circumstances, treatment against Gram-negative organisms must be initiated concomitantly.</p><p>Specific Gram-negative treatment <em><strong>must</strong></em> be initiated concomitantly if a Gram-negative pathogen is documented or suspected in patients with nosocomial or community acquired pneumonia.</p><p>Linezolid should be initiated only in a hospital environment and after consultation with a relevant specialist such as a microbiologist.</p><p>For further information see <span><u><a href=\"http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines/CON2030643\" target=\"_blank\">Letter sent to healthcare professionals in March 2007<font color=\"#800080\">Letter sent to healthcare professionals in March 2007</font></a></u></span></p><p>&#160;</p><p><em>Article citation: Drug Safety Update August 2007; Vol 1, issue 1: 6-7.</em></p>\r\n\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_END_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t", 
  "date_of_article": "2007-08-01", 
  "date_last_modified": "2010-08-24", 
  "_assets": [], 
  "_item_id": 330, 
  "summary": "Linezolid is not active against infections caused by Gram-negative pathogens, and treatment should be started only after specialist microbiological advice", 
  "body": "Article date: August 2007\n\nLinezolid (Zyvox▼) is an oxazolidinone antimicrobial, which selectively inhibits bacterial ribosomal translation; it also acts as a reversible monoamine oxidase inhibitor. Linezolid is indicated for treatment of nosocomial pneumonia, community acquired pneumonia, and complicated skin and soft tissue infections. Clinical efficacy has been shown for the Gram-positive aerobes Enterococcus faecium, Staphylococcus aureus, Streptococcus agalactiae, Streptococcus pneumoniae, and Streptococcus pyogenes.\n\nA study of intravascular catheter-related infections has shown increased mortality in patients who were treated with linezolid (78 of 363 [21·5%]) compared with those who were treated with vancomycin, dicloxacillin, or oxacillin (58 of 363 [16·0%]). The greatest imbalance occurred during treatment and within 7 days after discontinuation of study drug (43 of 363 [12%] deaths in the linezolid arm vs 22 of 363 [6%] in comparator arm). Mortality did not differ between groups of patients with pure Gram-positive infection (odds ratio 0·96 [95% CI 0·58–1·59]), but was significantly higher in the linezolid arm for patients with any other pathogen or no pathogen at baseline (2·48 [1·38–4·46], p=0·0162). More patients in the linezolid arm than in the comparator arm acquired Gram-negative infections during the study and died from Gram-negative and polymicrobial infections.\n\nPrescribing advice for linezolid was updated in March, 2007: linezolid is now indicated for treatment of complicated skin and soft tissue infections only when microbiological testing has established that infection is caused by susceptible Gram-positive bacteria. Patients with complicated skin and soft tissue infections who have known or possible co-infection with Gram-negative organisms should receive linezolid only if no alternative treatment options are available. In these circumstances, treatment against Gram-negative organisms must be initiated concomitantly.\n\nSpecific Gram-negative treatment must be initiated concomitantly if a Gram-negative pathogen is documented or suspected in patients with nosocomial or community acquired pneumonia.\n\nLinezolid should be initiated only in a hospital environment and after consultation with a relevant specialist such as a microbiologist.\n\nFor further information see [Letter sent to healthcare professionals in March 2007Letter sent to healthcare professionals in March 2007](http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines/CON2030643)\n\n \n\nArticle citation: Drug Safety Update August 2007; Vol 1, issue 1: 6-7.\n"
}